Generated by AI
enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for diseases with significant unmet medical needs. The company’s work centers on its proprietary DDX delivery platform, which is designed to deliver DNA and RNA-based therapies directly to mucosal tissues and other target organs. Its lead product candidate, detalimogene voraplasmid, is being developed as a monotherapy for non-muscle invasive bladder cancer, including difficult-to-treat high-risk cases. enGene Therapeutics Inc. also advances a broader pipeline of gene therapy programs aimed at localized treatment delivery in oncology and other therapeutic areas. Based in Montreal, Canada, the company plays a specialized role in the biotechnology market by pursuing tissue-targeted genetic therapies that seek to address complex diseases through precision delivery approaches.
Website4868 Rue Levy
Montreal, QC, H4R 2P1
Canada
The latest articles about ENGN.
enGene Therapeutics (ENGN) stock rose as Piper Sandler upgraded the company following updated mid-stage trial data for its lead asset, detalimogene. Read more here.
Summary of May 15's posts. Generated by AI.
Summary of May 14's posts. Generated by AI.
No summary yet.
Summary of May 8's posts. Generated by AI.
Investors talking about ENGN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.